Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence.
Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market Summary Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles. CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a c...